{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T16:31:36Z","timestamp":1787243496302,"version":"build-2736575974"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,11,3]],"date-time":"2016-11-03T00:00:00Z","timestamp":1478131200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2016,11,3]],"date-time":"2016-11-03T00:00:00Z","timestamp":1478131200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Siglec-2 undergoes constitutive endocytosis and is a drug target for autoimmune diseases and B cell-derived malignancies, including hairy cell leukaemia, marginal zone lymphoma, chronic lymphocytic leukaemia and non-Hodgkin\u2019s lymphoma (NHL). An alternative to current antibody-based therapies is the use of liposomal nanoparticles loaded with cytotoxic drugs and decorated with Siglec-2 ligands. We have recently designed the first Siglec-2 ligands (9-biphenylcarboxamido-4-\n                    <jats:italic>meta<\/jats:italic>\n                    -nitrophenyl-carboxamido-Neu5Ac\u03b12Me, 9-BPC-4-\n                    <jats:italic>m<\/jats:italic>\n                    NPC-Neu5Ac\u03b12Me) with simultaneous modifications at C-4 and C-9 position. In the current study we have used Saturation Transfer Difference (STD) NMR spectroscopy to monitor the binding of 9-BPC-4-\n                    <jats:italic>m<\/jats:italic>\n                    NPC-Neu5Ac\u03b12Me to Siglec-2 present on intact Burkitt\u2019s lymphoma Daudi cells. Pre-treatment of cells with periodate resulted in significantly higher STD NMR signal intensities for 9-BPC-4-\n                    <jats:italic>m<\/jats:italic>\n                    NPC-Neu5Ac\u03b12Me as the cells were more susceptible to ligand binding because\n                    <jats:italic>cis<\/jats:italic>\n                    -binding on the cell surface was removed. Quantification of STD NMR effects led to a cell-derived binding epitope of 9-BPC-4-\n                    <jats:italic>m<\/jats:italic>\n                    NPC-Neu5Ac\u03b12Me that facilitated the design and synthesis of C-2, C-3, C-4 and C-9 tetra-substituted Siglec-2 ligands showing an 88-fold higher affinity compared to 9-BPC-Neu5Ac\u03b12Me. This is the first time a NMR-based binding study of high affinity Siglec-2 (CD22) ligands in complex with whole Burkitt\u2019s lymphoma Daudi cells has been described that might open new avenues in developing tailored therapeutics and personalised medicine.\n                  <\/jats:p>","DOI":"10.1038\/srep36012","type":"journal-article","created":{"date-parts":[[2016,11,3]],"date-time":"2016-11-03T06:22:41Z","timestamp":1478154161000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Structural characterisation of high affinity Siglec-2 (CD22) ligands in complex with whole Burkitt\u2019s lymphoma (BL) Daudi cells by NMR spectroscopy"],"prefix":"10.1038","volume":"6","author":[{"given":"Paul D.","family":"Madge","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Maggioni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauro","family":"Pascolutti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moein","family":"Amin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Waespy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernadette","family":"Bellette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin J.","family":"Thomson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00f8rge","family":"Kelm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"von Itzstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Haselhorst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,11,3]]},"reference":[{"key":"BFsrep36012_CR1","unstructured":"(ACS), A. C. S. In What are the key statistics about Non-Hodgkin lymphoma? (American Cancer Society, Atlanta, GA, 2015)."},{"key":"BFsrep36012_CR2","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1002\/(SICI)1096-8652(199912)62:4<247::AID-AJH9>3.0.CO;2-T","volume":"62","author":"H Yang","year":"1999","unstructured":"Yang, H., Rosove, M. H. & Figlin, R. A. Tumor lysis syndrome occurring after the administration of rituximab in lymphoproliferative disorders: high-grade non-Hodgkin\u2019s lymphoma and chronic lymphocytic leukemia. Am J Hematol 62, 247\u2013250 (1999).","journal-title":"Am J Hematol"},{"key":"BFsrep36012_CR3","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/1741-7015-11-120","volume":"11","author":"N Jordan","year":"2013","unstructured":"Jordan, N., Lutalo, P. M. & D\u2019Cruz, D. P. Novel therapeutic agents in clinical development for systemic lupus erythematosus. BMC Med 11, 120, doi: 10.1186\/1741-7015-11-120 (2013).","journal-title":"BMC Med"},{"key":"BFsrep36012_CR4","doi-asserted-by":"publisher","first-page":"4778","DOI":"10.1182\/blood-2009-12-257386","volume":"115","author":"WC Chen","year":"2010","unstructured":"Chen, W. C. et al. In vivo targeting of B-cell lymphoma with glycan ligands of CD22. Blood 115, 4778\u20134786, doi: blood-2009-12-257386 [pii]10.1182\/blood-2009-12-257386 (2010).","journal-title":"Blood"},{"key":"BFsrep36012_CR5","doi-asserted-by":"publisher","first-page":"208","DOI":"10.3109\/10428194.2011.604755","volume":"53","author":"WC Chen","year":"2012","unstructured":"Chen, W. C., Sigal, D. S., Saven, A. & Paulson, J. C. Targeting B lymphoma with nanoparticles bearing glycan ligands of CD22. Leuk Lymphoma 53, 208\u2013210, doi: 10.3109\/10428194.2011.604755 (2012).","journal-title":"Leuk Lymphoma"},{"key":"BFsrep36012_CR6","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1046\/j.1432-1327.1998.2550663.x","volume":"255","author":"S Kelm","year":"1998","unstructured":"Kelm, S. et al. Functional groups of sialic acids involved in binding to siglecs (sialoadhesins) deduced from interactions with synthetic analogues. Eur J Biochem 255, 663\u2013672 (1998).","journal-title":"Eur J Biochem"},{"key":"BFsrep36012_CR7","doi-asserted-by":"publisher","first-page":"32200","DOI":"10.1074\/jbc.M702341200","volume":"282","author":"N Kimura","year":"2007","unstructured":"Kimura, N. et al. Human B-lymphocytes express alpha2-6-sialylated 6-sulfo-N-acetyllactosamine serving as a preferred ligand for CD22\/Siglec-2. J Biol Chem 282, 32200\u201332207, doi: M702341200 [pii]10.1074\/jbc.M702341200 (2007).","journal-title":"J Biol Chem"},{"key":"BFsrep36012_CR8","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1084\/jem.20011783","volume":"195","author":"S Kelm","year":"2002","unstructured":"Kelm, S., Gerlach, J., Brossmer, R., Danzer, C. P. & Nitschke, L. The ligand-binding domain of CD22 is needed for inhibition of the B cell receptor signal, as demonstrated by a novel human CD22-specific inhibitor compound. J Exp Med 195, 1207\u20131213 (2002).","journal-title":"J Exp Med"},{"key":"BFsrep36012_CR9","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1021\/cb400952v","volume":"9","author":"H Prescher","year":"2014","unstructured":"Prescher, H., Schweizer, A., Kuhfeldt, E., Nitschke, L. & Brossmer, R. Discovery of multifold modified sialosides as human CD22\/Siglec-2 ligands with nanomolar activity on B-cells. ACS Chem Biol 9, 1444\u20131450, doi: 10.1021\/cb400952v (2014).","journal-title":"ACS Chem Biol"},{"key":"BFsrep36012_CR10","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1002\/cmdc.201100407","volume":"7","author":"S Mesch","year":"2012","unstructured":"Mesch, S. et al. From a library of MAG antagonists to nanomolar CD22 ligands. ChemMedChem 7, 134\u2013143, doi: 10.1002\/cmdc.201100407 (2012).","journal-title":"ChemMedChem"},{"key":"BFsrep36012_CR11","doi-asserted-by":"publisher","first-page":"3616","DOI":"10.1002\/anie.201207267","volume":"52","author":"S Kelm","year":"2013","unstructured":"Kelm, S. et al. C-4 modified sialosides enhance binding to Siglec-2 (CD22): towards potent Siglec inhibitors for immunoglycotherapy. Angew Chem Int Ed Engl 52, 3616\u20133620, doi: 10.1002\/anie.201207267 (2013).","journal-title":"Angew Chem Int Ed Engl"},{"key":"BFsrep36012_CR12","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1021\/ja027691e","volume":"125","author":"AJ Benie","year":"2003","unstructured":"Benie, A. J., Moser, R., Bauml, E., Blaas, D. & Peters, T. Virus-ligand interactions: identification and characterization of ligand binding by NMR spectroscopy. J Am Chem Soc 125, 14\u201315, doi: 10.1021\/ja027691e (2003).","journal-title":"J Am Chem Soc"},{"key":"BFsrep36012_CR13","doi-asserted-by":"publisher","first-page":"1910","DOI":"10.1002\/anie.200704872","volume":"47","author":"T Haselhorst","year":"2008","unstructured":"Haselhorst, T. et al. Avian influenza H5-containing virus-like particles (VLPs): host-cell receptor specificity by STD NMR spectroscopy. Angew Chem Int Ed Engl 47, 1910\u20131912, doi: 10.1002\/anie.200704872 (2008).","journal-title":"Angew Chem Int Ed Engl"},{"key":"BFsrep36012_CR14","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1021\/ja044434w","volume":"127","author":"B Claasen","year":"2005","unstructured":"Claasen, B., Axmann, M., Meinecke, R. & Meyer, B. Direct observation of ligand binding to membrane proteins in living cells by a saturation transfer double difference (STDD) NMR spectroscopy method shows a significantly higher affinity of integrin alpha(IIb)beta3 in native platelets than in liposomes. J Am Chem Soc 127, 916\u2013919, doi: 10.1021\/ja044434w (2005).","journal-title":"J Am Chem Soc"},{"key":"BFsrep36012_CR15","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1002\/anie.200905941","volume":"49","author":"S Mari","year":"2010","unstructured":"Mari, S. et al. 2D TR-NOESY experiments interrogate and rank ligand-receptor interactions in living human cancer cells. Angew Chem Int Ed Engl 49, 1071\u20131074, doi: 10.1002\/anie.200905941 (2010).","journal-title":"Angew Chem Int Ed Engl"},{"key":"BFsrep36012_CR16","doi-asserted-by":"crossref","unstructured":"Mari, S., Serrano-G\u00f3mez, D., Ca\u00f1ada, F. J., Corb\u00ed, A. L. & Jim\u00e9nez-Barbero, J. 1D Saturation Transfer Difference NMR Experiments on Living Cells: The DC-SIGN\/Oligomannose Interaction. Angew Chem Int Ed Engl, 296\u2013298 (2005).","DOI":"10.1002\/anie.200461574"},{"key":"BFsrep36012_CR17","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1002\/chem.201503126","volume":"22","author":"B Farina","year":"2016","unstructured":"Farina, B. et al. A Combined NMR and Computational Approach to Determine the RGDechi-hCit-alphav beta3 Integrin Recognition Mode in Isolated Cell Membranes. Chemistry 22, 681\u2013693, doi: 10.1002\/chem.201503126 (2016).","journal-title":"Chemistry"},{"key":"BFsrep36012_CR18","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s10858-016-0025-1","volume":"64","author":"A Antanasijevic","year":"2016","unstructured":"Antanasijevic, A. et al. Application of virus-like particles (VLP) to NMR characterization of viral membrane protein interactions. J Biomol NMR 64, 255\u2013265, doi: 10.1007\/s10858-016-0025-1 (2016).","journal-title":"J Biomol NMR"},{"key":"BFsrep36012_CR19","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1093\/glycob\/cwu109","volume":"25","author":"A Albohy","year":"2015","unstructured":"Albohy, A., Richards, M. R. & Cairo, C. W. Mapping substrate interactions of the human membrane-associated neuraminidase, NEU3, using STD NMR. Glycobiology 25, 284\u2013293, doi: 10.1093\/glycob\/cwu109 (2015).","journal-title":"Glycobiology"},{"key":"BFsrep36012_CR20","doi-asserted-by":"publisher","first-page":"2421","DOI":"10.1002\/cbic.201100483","volume":"12","author":"A Maggioni","year":"2011","unstructured":"Maggioni, A., Meier, J., Routier, F., Haselhorst, T. & Tiralongo, J. Direct investigation of the Aspergillus GDP-mannose transporter by STD NMR spectroscopy. Chembiochem 12, 2421\u20132425, doi: 10.1002\/cbic.201100483 (2011).","journal-title":"Chembiochem"},{"key":"BFsrep36012_CR21","doi-asserted-by":"publisher","first-page":"2784","DOI":"10.1002\/cbic.200800526","volume":"9","author":"A Maggioni","year":"2008","unstructured":"Maggioni, A., von Itzstein, M., Tiralongo, J. & Haselhorst, T. Detection of ligand binding to nucleotide sugar transporters by STD NMR spectroscopy. Chembiochem 9, 2784\u20132786, doi: 10.1002\/cbic.200800526 (2008).","journal-title":"Chembiochem"},{"key":"BFsrep36012_CR22","doi-asserted-by":"publisher","first-page":"7212","DOI":"10.1021\/ja8016939","volume":"130","author":"FM Assadi-Porter","year":"2008","unstructured":"Assadi-Porter, F. M. et al. Direct NMR detection of the binding of functional ligands to the human sweet receptor, a heterodimeric family 3 GPCR. J Am Chem Soc 130, 7212\u20137213, doi: 10.1021\/ja8016939 (2008).","journal-title":"J Am Chem Soc"},{"key":"BFsrep36012_CR23","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1002\/anie.201004116","volume":"50","author":"T Haselhorst","year":"2011","unstructured":"Haselhorst, T. et al. Recognition of the GM3 ganglioside glycan by Rhesus rotavirus particles. Angew Chem Int Ed Engl 50, 1055\u20131058, doi: 10.1002\/anie.201004116 (2011).","journal-title":"Angew Chem Int Ed Engl"},{"key":"BFsrep36012_CR24","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1016\/j.bbrc.2007.05.204","volume":"359","author":"T Haselhorst","year":"2007","unstructured":"Haselhorst, T. et al. Direct detection of ligand binding to Sepharose-immobilised protein using saturation transfer double difference (STDD) NMR spectroscopy. Biochem Biophys Res Commun 359, 866\u2013870, doi: S0006-291X(07)01142-4 [pii]10.1016\/j.bbrc.2007.05.204 (2007).","journal-title":"Biochem Biophys Res Commun"},{"key":"BFsrep36012_CR25","doi-asserted-by":"publisher","first-page":"3669","DOI":"10.1021\/ja710854r","volume":"130","author":"C Rademacher","year":"2008","unstructured":"Rademacher, C., Krishna, N. R., Palcic, M., Parra, F. & Peters, T. NMR experiments reveal the molecular basis of receptor recognition by a calicivirus. J Am Chem Soc 130, 3669\u20133675, doi: 10.1021\/ja710854r (2008).","journal-title":"J Am Chem Soc"},{"key":"BFsrep36012_CR26","doi-asserted-by":"publisher","first-page":"1936","DOI":"10.1002\/cbic.201300298","volume":"14","author":"A Maggioni","year":"2013","unstructured":"Maggioni, A. et al. Characterisation of CMP-sialic acid transporter substrate recognition. Chembiochem 14, 1936\u20131942, doi: 10.1002\/cbic.201300298 (2013).","journal-title":"Chembiochem"},{"key":"BFsrep36012_CR27","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/S0076-6879(03)01047-4","volume":"363","author":"EC Brinkman-Van der Linden","year":"2003","unstructured":"Brinkman-Van der Linden, E. C. & Varki, A. Probing for masked and unmasked siglecs on cell surfaces. Methods Enzymol 363, 113\u2013120, doi: 10.1016\/S0076-6879(03)01047-4 S0076687903010474 [pii] (2003).","journal-title":"Methods Enzymol"},{"key":"BFsrep36012_CR28","doi-asserted-by":"publisher","first-page":"7469","DOI":"10.1073\/pnas.95.13.7469","volume":"95","author":"N Razi","year":"1998","unstructured":"Razi, N. & Varki, A. Masking and unmasking of the sialic acid-binding lectin activity of CD22 (Siglec-2) on B lymphocytes. Proc Natl Acad Sci USA 95, 7469\u20137474 (1998).","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFsrep36012_CR29","first-page":"44","volume":"89","author":"AA Demin","year":"2011","unstructured":"Demin, A. A. et al. Late results of high-dose immunosuppressive therapy with auotransplantation of hematopoietic stem cells in patients with severe refractory systemic lupus erythematosus Klin Med (Mosk) 89, 44\u201349 (2011).","journal-title":"Klin Med (Mosk)"},{"key":"BFsrep36012_CR30","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1016\/J.Bmc.2011.01.060","volume":"19","author":"HHM Abdu-Allah","year":"2011","unstructured":"Abdu-Allah, H. H. M. et al. CD22-Antagonists with nanomolar potency: The synergistic effect of hydrophobic groups at C-2 and C-9 of sialic acid scaffold. Bioorgan Med Chem 19, 1966\u20131971, doi: 10.1016\/J.Bmc.2011.01.060 (2011).","journal-title":"Bioorgan Med Chem"},{"key":"BFsrep36012_CR31","doi-asserted-by":"crossref","unstructured":"Okamoto, K., Kondo, T. & Goto, T. Bull. Chem. Soc. Jpn. 631 (1987).","DOI":"10.1246\/bcsj.60.631"},{"key":"BFsrep36012_CR32","unstructured":"Pascolutti, M., Madge, P., Thomson, R. & von Itzstein, M. Journal of Organic Chemistryin press (2015)."},{"key":"BFsrep36012_CR33","doi-asserted-by":"publisher","first-page":"2728","DOI":"10.1248\/cpb.40.2728","volume":"40","author":"K Okamoto","year":"1992","unstructured":"Okamoto, K., Hasegawa, T., Toyomaki, Y., Yamakawa, M. & Okukado, N. 3 beta-Hydroxysialic acid glycosides. I. Calcium-binding ability and chemical and enzymatic stabilities. Chemical & pharmaceutical bulletin 40, 2728\u20132734 (1992).","journal-title":"Chemical & pharmaceutical bulletin"},{"key":"BFsrep36012_CR34","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/J.Idairyj.2011.01.005","volume":"21","author":"H Koliwer-Brandl","year":"2011","unstructured":"Koliwer-Brandl, H. et al. Lectin inhibition assays for the analysis of bioactive milk sialoglycoconjugates. Int Dairy J 21, 413\u2013420, doi: 10.1016\/J.Idairyj.2011.01.005 (2011).","journal-title":"Int Dairy J"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/srep36012.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep36012","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep36012.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T19:35:49Z","timestamp":1672860949000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/srep36012"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,3]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2016,12,21]]}},"alternative-id":["BFsrep36012"],"URL":"https:\/\/doi.org\/10.1038\/srep36012","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11,3]]},"assertion":[{"value":"5 January 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2016","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"36012"}}